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TBIO-12. THE SPECTRUM OF MITOCHONDRIAL DNA (MTDNA) 
MUTATIONS IN PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) 
TUMORS
Kristiyana Kaneva1, Petr Triska2, Daria Merkurjev3, Moiz Bootwalla3, 
Jennifer Cotter3, Dejerianne Ostrow3, Katrina O’Halloran3, Jaclyn Biegel3, 
and Xiaowu Gai3; 1Ann & Robert H. Lurie Children’s Hospital of 
Chicago, Chicago, IL, USA, 2Charles University, Prague, Czech Republic, 
3Children’s Hospital Los Angeles, Los Angeles, California, USA
To explore the role of mitochondrial DNA mutations in pediatric CNS 
tumors, we analyzed 749 tumor-normal paired whole genome sequencing 
data sets from the Children’s Brain Tumor Tissue Consortium (CBTTC). We 
detected 307 somatic mtDNA mutations in 222 CNS tumors (29.6%). Most 
frequently observed were missense mutations (38.1%). We also detected 34 
loss-of-function mutations. Different pediatric CNS tumor subtypes have 
distinct mtDNA mutation profiles. For categorical comparisons, we ana-
lyzed subtypes with at least 15 samples. The highest number of mtDNA 
mutations per tumor sample was in meningiomas (0.85), while atypical 
teratoid rhabdoid tumors (ATRTs) had the lowest number per sample 
(0.18). High-grade gliomas had a higher number of mtDNA mutations per 
sample than low-grade gliomas (0.56 vs. 0.31) (p = 0.0011), with almost 
twice as many missense mtDNA mutations per sample (0.22 vs. 0.13) (p < 
0.001), and higher average heteroplasmy levels (11% vs. 9%). The average 
heteroplasmy was 10.1%, ranging from 15.6% in medulloblastoma to 
6.36% in schwannoma suggesting that these are clonal alterations and not 
artifacts. Intriguingly, the two chordoma patients in the CBTTC database 
had an identical heteroplasmic m.10971G>A MT-ND4 nonsense muta-
tion. Similarly, our patient with recurrent gliofibroma harbored the same 
somatic MT-ND4 synonymous variant (m.10700A>G) detected at 53% 
heteroplasmy in the initial tumor, 79% in the first recurrence, and 97% in 
the second recurrence. Although the functional consequences of these al-
terations are not yet understood, our findings suggest that sequencing the 
mtDNA genome may be used to characterize CNS tumors at diagnosis and 
monitor disease progression.
TBIO-13. USE OF NEXT GENERATION SEQUENCING TO IDENTIFY 
MOVE DRIVERS OF CRYPTIC, CLINICALLY AGGRESSIVE BRAIN 
TUMORS
Subhi Talal Younes, Amanda Boudreaux, Kristin Weaver, Cynthia Karlson, 
and Betty Herrington; University of Mississippi Medical Center, Jackson, 
MS, USA
INTRODUCTION: Next generation sequencing (NGS) is an emerging 
technology which allows for in-depth analysis of pediatric brain tumors. 
NGS has particular use in the context of ambiguous or aggressive neoplasms, 
where it can be leveraged to discover novel drivers, inform pathologic clas-
sification, and direct targeted therapies. OBJECTIVE: The objective of this 
case series was to utilize NGS technology to illuminate the biology of aggres-
sive brain tumors with ambiguous pathologic features and clinically aggres-
sive behavior. METHODS: FFPE tumor tissue and matched germline DNA 
were subjected to whole exome sequencing (WES). Data were analyzed ac-
cording to the GATK pipeline. RESULTS: The first case is a 6-year-old male 
who presented with innumerable foci of leptomeningeal nodules throughout 
the neuroaxis. Original pathology was CNS embryonal tumor. WES iden-
tified loss of chromosome 1p and 16q with gain of 1q and amplification 
of MYC and OTX2 loci (cytogenetic aberrations characteristic of group 3 
medulloblastoma) and a deleterious mutation in BCL7B, a known tumor 
suppressor gene. The second case is a 2-year-old female who presented with 
a parietal lobe mass diagnosed as high grade neuroepithelial tumor with 
C11orf95 translocation, but no RELA fusion. WES revealed loss of small 
region of chromosome 2p and mutations in IDH3G, TRAF2, and JMJD1C, 
suggesting novel targets for further study. CONCLUSIONS: In both cases, 
NGS studies were able to shed light on the underlying tumor biology and/or 
refine the pathologic diagnosis. These data underscore the utility of applying 
NGS technology to study the biology of pediatric brain tumors.
TBIO-14. CHARACTERISATION OF THE ARGININE PATHWAY 
ENZYMES IN PAEDIATRIC BRAIN TUMOURS TO DETERMINE 
SUSCEPTIBILITY TO THERAPEUTIC ARGININE DEPLETION
Eleanor Bishop, Monika Dimitrova, Lisa Storer, Richard Grundy, and 
Madhumita Dandapani; University of Nottingham, Nottingham, United 
Kingdom
INTRODUCTION: Extracellular arginine dependency (auxotrophy) is 
increasingly being recognised in several tumours. This is due to the inability 
of cancer cells to recycle or synthesise intracellular arginine through the 
urea cycle pathway compared to normal cells. Whilst adult glioblastoma 
is known to exhibit this, the expression of the arginine pathway enzymes 
has not been delineated in paediatric brain tumours.  METHODS: We 
used immunohistochemical methods to stain for arginine pathway en-
zymes in Paediatric High grade glioma (pHGG), low grade glioma (pLGG) 
and medulloblastoma (MB) tumour tissue microarrays (TMAs). The anti-
bodies detected protein expression of the metaboliser Arginase (Arg2), 
recycling enzymes ornithine transcarbamoylase (OTC), Arginosuccinate 
synthetase (ASS1) and arginosuccinate lyase (ASL) as well as the trans-
porter SLC7A1. RESULTS: Deficiency of OTC, ASS1 and ASL were seen in 
92%, 98% and 93% of pHGG samples (n=156) respectively, with deficiency 
defined as low (<20%) or negative antibody expression. Identical results 
were seen in pLGG (n=98) - 83%, 97% and 95% were deficient in OTC, 
ASS1 and ASL. Both pHGG and pLGG highly expressed SLC7A1 and Arg2, 
demonstrating that they could transport and utilise arginine. In MB (n=82), 
this auxotrophic signature was again seen in 90% of TMAs with absent or 
low expression of OTC, ASS1 and ASL and high Arg2 and SLC7A1 expres-
sion. CONCLUSIONS: These results show that pHGG, pLGG and MB are 
arginine auxotrophs. Pegylated arginase (BCT-100) is currently in Phase I/II 
trials in relapsed pHGG. Our results suggest that therapeutic arginine deple-
tion may also be useful in MB and pLGG.
TBIO-15. MODELING DEVELOPMENTAL GENE EXPRESSION 
DYNAMICS AT CELLULAR RESOLUTION TO INTERPRET 
PEDIATRIC BRAIN TUMOR TRANSCRIPTIONAL PROGRAMS
Selin Jessa1,2, Nisha Kabir1,2, Maria Vladoiu3, Steven Hébert2, 
Michael D. Taylor3, Nada Jabado1,4, and Claudia L. Kleinman1,2; 1McGill 
University, Montreal, QC, Canada, 2Lady Davis Institute for Medical 
Research, Montreal, QC, Canada, 3The Hospital for Sick Children, 
Toronto, ON, Canada, 4The Research Institute of the McGill University 
Health Centre, Montreal, QC, Canada
A central challenge in understanding the biology of pediatric brain tumors 
is defining the cellular and molecular context where oncogenesis occurs. We 
hypothesize that spatiotemporally restricted cell types are uniquely suscep-
tible to specific genetic alterations, which alter normal neurodevelopmental 
programs and ultimately lead to oncogenesis. The resulting tumors retain 
some transcriptomic features of their lineage of origin. To delineate these 
origins, we assembled a densely sampled developmental time course of the 
mouse forebrain and pons, doubling our recently published single-cell atlas. 
This dataset comprises >100,000 cells at 9 timepoints from E10-P6. How-
ever, while single cell transcriptomics reveal rich gene dynamics during cell 
differentiation, interpretation of individual genes can be challenging due 
to data sparsity. Leveraging this time-series, we present strategies to model 
and visualize the expression of a given gene across differentiation of dis-
tinct lineages. We demonstrate an interactive web app to interrogate the ex-
pression of genes or gene sets during brain development, extract temporally 
correlated genes, and search active transcription factor regulatory modules. 
Finally, we profile the expression of core transcriptional programs of sev-
eral pediatric brain tumor entities during development. Our analyses reveal 
genes with restricted expression patterns that elucidate tumor etiology. More 
broadly, these resources harness single cell data to enable exploration of 
neurodevelopmental gene programs with great relevance to pediatric brain 
tumor oncogenesis.
TBIO-16. NOTCH1 PATHWAY AS TARGET FOR DRUG 
INTERVENTION FOR HISTONE 3 G34R MUTATED PHGG
Katie Foot1, Anbarasu Lourdusamy2, Sofia Christou2, Ruman Rahman2, 
Robert Layfield2, Richard Grundy2, and Farhana Haque2; 1University of 
Birmingham, Birmingham, United Kingdom, 2University of Nottingham, 
Nottingham, United Kingdom
There have been no significant improvements in the treatments for child-
hood High-Grade Glioma (pHGG) and Diffuse Intrinsic Pontine Glio-
blastoma (DIPG), which continue to have a very poor prognosis. These 
cancers harbor mutations affecting histone 3 (H3) proteins; 80% of DIPGs 
with histone H3 K27M somatic mutations whilst 30% of pHGGs exhibit 
H3.3 G34R or G34V mutations. We have generated and validated a his-
tone 3.3 G34R mutant-specific antibody and investigated the downstream 
effects of H3.3 G34R mutations in pHGG. In order to identify the genes 
that may be deregulated by G34R mutant histone expression, we have 
performed chromatin immunoprecipitation (ChIP) assays with our H3.3 
G34R and wild type H3 antibodies, using pHGG H3 G34R mutant and 
wild-type cell lines. Initial analyses of ChIP data have implicated deregu-
lation of cell-signaling pathways including Notch1, Hedgehog, PPAR-1, 
PLC-beta and Androgen, in H3 G34R mutated pHGG. We are currently 
determining the effects of altered expression of Notch1 pathway compo-
nents on tumorigenesis of H3 G34R mutated pHGG, through gene and 
protein expression and inhibition assays. Specifically we find that the 
Notch1 pathway component HES1 shows increased expression in G34R 
mutant cells compared to controls, directing our evaluation of the utility 
of gamma-secretase inhibitors as potential therapeutics. These analyses 
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